Magromag

Nitrofurantoin, the active ingredient in Magromag, is a nitrofuran antibiotic presented as an oral dosage form for oral use. It treats uncomplicated urinary tract infections by targeting susceptible bacteria in the urinary tract, primarily in adult patients.

GNH USA supplies Magromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions, including Europe, Asia and Africa, and the Americas.

Nitrofurantoin is indicated for infections of the urinary tract and works by eliminating susceptible bacteria.

- Uncomplicated urinary tract infection: eradicates the causative uropathogens and resolves symptoms. - Acute cystitis: provides rapid bactericidal activity in the bladder, reducing infection duration. - Prophylaxis of recurrent urinary tract infection: decreases the frequency of future episodes when used as a preventive regimen.

Nitrofurantoin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Loss of appetite - Headache - Diarrhea

Serious or Rare Side Effects: - Pulmonary toxicity (including interstitial pneumonitis) - Hepatic injury (elevated enzymes or hepatitis) - Hemolytic anemia in patients with G6PD deficiency

Before prescribing Nitrofurantoin, clinicians should evaluate several safety considerations to minimize risk.

Renal function assessment: evaluate creatinine clearance and avoid use in severe renal impairment. Pregnancy: avoid use unless benefits outweigh potential risks, as safety data are limited. G6PD deficiency: contraindicated because of risk of hemolysis. Elderly patients: monitor renal function and adjust therapy as needed. Drug interactions: review concomitant medications for potential absorption or toxicity issues. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Nitrofurantoin can interact with other medicines, altering its absorption or increasing toxicity.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce nitrofurantoin absorption; separate dosing by at least 2 hours. - Fluoroquinolones: combined use may increase risk of tendon toxicity; avoid co‑administration. - Warfarin: nitrofurantoin may potentiate anticoagulant effect; monitor INR closely.

Moderate Interactions (Monitor Closely): - Probenecid: may increase nitrofurantoin plasma levels; observe for signs of toxicity. - Diuretics: altered urinary concentration can affect drug efficacy; monitor clinical response.